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ABSTRACT
Objective: This study investigated whether the herbal plant Spirulina could be used in crude form as an alternative therapy to artemisinin combination 
therapy (ACT) for the treatment of malaria caused by Plasmodium falciparum.
Methods: Mice infected by Plasmodium berghei were treated orally with a single dose of Spirulina (200 or 400 mg/kg body weight [BW]), 
dihydroartemisinin-piperaquine as a type of ACT, or a combination of the two. The level of parasitemia was then compared between the groups during 
the 4-day post-infection period.
Results: There was a significant difference in the change in the level of parasitemia from day 0 to day 4 between groups (Kruskal–Wallis test, P < 0.05). 
Mice that were treated with both doses of Spirulina alone had a significantly higher parasitemia density than those treated with ACT alone. However, 
the combination of Spirulina and ACT had a synergistic effect, with 200 mg/kg BW Spirulina + ACT giving significantly better results than ACT alone.
Conclusion: These findings indicate that treatment with Spirulina alone cannot be used as antimalarial medication, but its combination with ACT can 
lead to enhanced antimalarial activity.
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INTRODUCTION
Malaria is a disease that is transmitted by female Anopheles mosquitoes 
carrying the Plasmodium parasite [1]. According to the World Health 
Organization (WHO), there were 214 million cases of malaria and 
438,000 malaria deaths worldwide in 2015, with Africa having the 
greatest number of cases [2]. In Indonesia, malaria remains one of the 
major health problems, with a prevalence rate of 6% and an incidence 
of 1.9% according to Indonesian Basic Health Research in 2013.
Artemisinin combination therapy (ACT) is currently recommended by the 
WHO for the treatment of malaria caused by Plasmodium falciparum [3], 
as artemisinin can rapidly reduce the level of parasites in the blood. 
However, resistance to this drug was detected in a number of countries 
in 2015, and there is concern that this resistance will spread to other 
countries, which would pose a major health problem because no other 
antimalarials with an equivalent efficacy have been found to date [3].
Medicinal plants offer a safe and cheap alternative treatment for 
malaria with few side effects. Consequently, many studies have 
investigated whether the compounds they contain can be combined 
with standard drugs to resolve the current resistance problem [4]. 
Spirulina algae contain proteins, carbohydrates, fats, vitamins, and 
some types of pigments [5] and have been shown to have not only 
anti-inflammatory, antiviral, antioxidant, and anticancer effects [6-9] 
but also antimalarial activity through neutrophil blockage and pro-
inflammatory cytokines [7]. Furthermore, Spirulina is classified as safe 
for use due to its minimal side effects even after long-term use [6].
One of the most studied pigments in Spirulina is phycocyanin, which can 
act as an anti-inflammatory, antimicrobial, and antimalarial [5,6,10,11] 
and is known to inhibit nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, which plays a role in the development of oxidative 
stress [5]. Consequently, phycocyanin is considered to be of biomedical 
interest, and the effect of low concentrations of phycocyanin on 
parasitemia levels in sensitive or chloroquine-resistant parasites 
has previously been investigated. In addition, phycocyanin is safe to 
use in combination with other antimalarials [10]. The beta-carotene 
content of Spirulina also plays an important role as an antioxidant and 
anti-inflammatory [11], inhibiting the pro-inflammatory cytokines 
produced by macrophages in a way similar to phycocyanin [6].
No studies to date have used Spirulina in combination with ACT 
for the treatment of malaria. Therefore, this study investigated the 
effect of treating mice infected with Plasmodium berghei with a 
combination of Spirulina and dihydroartemisinin-piperaquine (DHP), 
which is a type of ACT that has been shown to have high antimalarial 
efficacy [2].
METHODS
Study animals and treatment groups
This study used 3–4-month-old male Swiss mice that weighed 20–25 mg. 
The mice were kept in a laboratory at the Research and Development 
Center of Indonesian Ministry of Health (Salemba, Indonesia) between 
April and December 2016, where they were provided with standard 
food and clean drinking water each day. They were housed before the 
experiment for acclimation to the surrounding environment.
Federer’s formula showed that the minimum number of experimental 
animals that needed to be used was four per treatment group. 
Therefore, five mice were included in each group in anticipation 
that some mice would drop out of the experiment. The mice (n=30) 
were divided into six treatment groups: A positive control group that 
was given DHP, a negative control group that received no treatment, 
twp Spirulina treatment groups (200 and 400 mg/kg body weight 
[BW]), and two combined treatment groups (200 and 400 mg/kg BW 
Spirulina + DHP).
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Experimental procedure
Parasitemia was induced in donor mice, following which blood 
suspensions from these donors were diluted to 2% parasitemia 
concentration. Each experimental mouse was injected with up to 1 ml 
of the diluted infected blood intraperitoneally and left for 24 h for the 
parasites to breed and has an effect on the mice.
After 24 h, the mice in each group were administered their 
respective treatment orally using a sonde that was carefully inserted 
into the stomach of the mouse. DHP was administered at a dose 
of 49.3 mg/kg BW, which was calculated by converting the dose 
of 4 mg/kg BW dihydroartemisinin that is recommended in the 
Malaria Case Management Manual in Indonesia [12] using a surface-
based calculation with a constant factor for each species. Spirulina was 
administered at 200 and 400 mg/kg BW, according to Siswantoro [13].
The level of parasitemia in each group was assessed using the 4-day 
suppressive tests introduced by Trager and Jensen [14]. Before 
treatment and each day for 4 days after treatment, a blood sample was 
collected from the lateral vein in the tail of each mouse at 1–2 mm from 
the tip using sterile scissors. A blood smear was made on a glass slide 
and left to dry in the air, and was then fixed with 90% methanol and 
stained using Giemsa stain diluted with distilled water. The level of 
parasitemia in the peripheral blood smear was then calculated in 1000 
red blood cells at ×1000 magnification under a microscope. On day 8, 
the mice were terminated by cervical dislocation, following one of the 
termination guidelines produced by the Institutional Animal Care and 
Use Committee [12].
Statistical analysis
Since the data consisted of >2 unpaired groups and >50 samples, the 
Shapiro–Wilk test was used to examine the normality of the data set. 
This showed that the data were not normally distributed. Therefore, 
the Kruskal–Wallis test was used to compare the levels of parasitemia 
among groups and the Mann–Whitney U-test was used for post hoc 
analysis. All analyses were performed in SPSS version 20 with a 
significance level of p<0.05.
RESULTS
The level of parasitemia increased each day in the negative control 
group and 200 and 400 mg/kg BW Spirulina treatment groups but 
generally decreased in the positive control group and Spirulina + ACT 
treatment groups (Table 1). At 4-day post-infection (H4), the highest 
rate of parasitemia was observed in 400 mg/kg BW Spirulina group 
(60.42%), while the lowest rate was observed in 400 mg/kg BW 
Spirulina + ACT group (0.5%).
Both of Spirulina + ACT treatment groups experienced decreased 
parasitemia levels between the day of infection with P. berghei (H0) 
and H4, though with slight increases on H2 and H4 (Table 1). They also 
had lower mean parasitemia rates than the positive control group, with 
this difference being significant for 200 mg/kg BW + ACT treatment 
group (Tables 2 and 3). In addition, 200 mg/kg BW Spirulina treatment 
group exhibited slightly greater reductions in parasitemia levels than 
400 mg/kg BW Spirulina treatment group (Sp 200 mg/kg WB = −0.38% 
and Sp 400 mg/kg WB = −0.22%). By contrast, the negative control 
group and two Spirulina treatment groups had significantly higher 
parasitemia levels than the positive control group (Tables 2 and 3).
The positive control group and the two combined treatment groups had 
the highest rates of parasite growth inhibition (98.88–99.10%), while 
400 mg/kg BW Spirulina treatment group had the lowest (−9.34%) 
(Table 1). However, there was little difference between Spirulina alone 
and combined treatment groups.
Table 1: Effects of Spirulina and ACT on the levels of parasitemia and inhibition of parasite growth in mice infected with Plasmodium 
berghei from 0 to 4 days after infection (H0–H4)
Treatment group n H0 H1 H2 H3 H4 P H4‑H0
P GI P GI P GI P GI P GI
Negative control 5 0.8 0 10.6 0 28.96 0 48.44 0 55.26 0 54.46
Positive control 5 0.52 35 1.72 83.77 0.96 96.69 0.48 99.01 0.62 98.88 0.1
Sp 1 5 0.78 2.50 6.32 40.38 18.2 37.15 43.52 10.16 56.1 −1.52 55.32
Sp 2 5 0.78 2.50 6.64 37.36 26.94 6.98 47.02 2.93 60.42 −9.34 59.64
Combination 1 5 0.98 −22.50 0.56 95.09 0.64 97.79 0.52 99.01 0.6 98.91 −0.38
Combination 2 5 0.72 10.00 1.76 83.40 0.54 98.14 0.46 99.05 0.5 99.10 −0.22
Negative control, no treatment; positive control, ACT; Sp 1, 200 mg/kg BW Spirulina; Sp 2, 400 mg/kg BW Spirulina; combination 1, 200 mg/kg BW 
Spirulina+ACT; combination 2, 400 mg/kg BW Spirulina+ACT; P - Parasitemia level; GI - Growth inhibition ACT: Artemisinin combination therapy, BW: Body weight
Table 3: Post hoc analysis of the differences in parasitemia 
density among treatment groups
Treatment group Asymp. 
Sig. (two‑tailed)
Significance
Positive control Sp 1 0.009 *
Sp 2 0.009 *
Combination 1 0.012 *
Combination 2 0.180 NS
Negative control 0.009 *
Sp 1 Sp 2 0.465 NS
Combination 1 0.009 *
Combination 2 0.008 *
Negative control 0.917 NS
Sp 2 Combination 1 0.009 *
Combination 2 0.008 *
Negative control 0.76 NS
Combination 1 Combination 2 0.138 NS
Negative control 0.009 *
Combination 2 Negative control 0.008 *
*p<0.05, Mann–Whitney U-test. Positive control, ACT; Sp 1, 200 mg/kg BW 
Spirulina; Sp 2, 400 mg/kg BW Spirulina; combination 1, 200 mg/kg BW 
Spirulina+ACT; combination 2, 400 mg/kg BW Spirulina+ACT; negative control, 
no treatment
Table 2: Differences in the parasitemia density in mice infected 
with Plasmodium berghei that had been administered Spirulina 
and/or ACT
Treatment group n Brinkman index p value
Positive control 5 0.00 (−0.10–0.40) < 0.000
Negative control 5 51.80 (49.00–69.00)
Sp 1 5 55.00 (40.80–68.50) 
Sp 2 5 58.80 (53.60–69.30)
Combination 1 5 −0.30 (−0.70–−0.10) 
Combination 2 5 0.00 (−1.00–0.00)
Kruskal–Wallis test. See Table 3 for the results of the post hoc. Positive control, 
ACT; Sp 1, 200 mg/kg BW Spirulina; Sp 2, 400 mg/kg BW Spirulina; combination 
1, 200 mg/kg BW Spirulina+ACT; combination 2, 400 mg/kg BW Spirulina+ACT; 
negative control, no treatment. ACT: Artemisinin combination therapy
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DISCUSSION
This study investigated the effects of using two different doses of 
Spirulina alone and in combination with ACT to treat mice infected 
with P. berghei. Neither of the Spirulina treatment groups exhibited any 
antimalarial effects, with the parasitemia level increasing each day in 
a way similar to the negative control group. However, a combination 
of Spirulina and ACT exhibited enhanced antimalarial activity, with a 
lower parasitemia level than the positive control group that was treated 
with ACT therapy.
Parasitic infections can induce the production of hydrogen peroxide 
and the formation of hydroxyl radicals (OH•), which cause apoptosis 
and oxidative stress [15], and can also lead to an increase in lipid 
peroxidation and a decrease in antioxidant capacity in the host’s 
body [16]. The body responds to the presence of the infection by 
increasing macrophage and neutrophil phagocytosis activities, which 
leads to an imbalance between the antioxidant activity and free radicals 
in the body [17].
Spirulina has a potent antioxidant capacity through its ability to prevent 
lipid peroxidation and DNA damage and to increase the production of 
antioxidant enzymes [18]. The antioxidant and anti-inflammatory 
effects of this plant result from the phycocyanin, vitamins, and other 
substances it contains. Phycocyanin can inhibit the activity of NADPH 
oxidase, which is involved in the development of oxidative stress, and 
the vitamins in Spirulina, such as Vitamins E and C, also enhance the 
plant’s antioxidant and anti-inflammatory effects [5]. In addition, 
phycocyanin has an antimalarial effect through the destruction of 
hemozoin polymerization [10]. Consequently, the consumption of 
Spirulina can improve the workings of the immune system, and it has 
been proposed that phycocyanin and beta-carotene pigments could 
act synergistically with ACT [5]. Therefore, the synergistic antimalarial 
effect of Spirulina when used in combination with ACT likely resulted 
from the antioxidant activities that are associated with the beta-
carotene and phycocyanin pigments it contains.
Given these activities of the components of Spirulina, it was somewhat 
surprising that Spirulina alone did not exhibit antimalarial activity. 
It has previously been shown that phycocyanin obtained from 
Nostoc spp. has antimalarial activity and is a powerful antioxidant [10], 
whereas phycocyanin isolated from Spirulina platensis has a lower 
inhibitory effect on parasitic growth than artemisinin and is a weak 
antioxidant [19]. These different findings result from the different 
origins of the phycocyanin and the different extraction processes that 
were used, which will have affected the level of phycocyanin purity [19]. 
The present study used crude Spirulina that was sold commercially, the 
specific composition of which was unknown. Therefore, it is suspected 
that this contained some substance that acted as an antagonist of the 
antimalarial activity possessed by phycocyanin.
CONCLUSION
This study investigated the use of crude Spirulina as an antimalarial. 
It was found that Spirulina was not able to function as an antimalarial 
when used on its own. However, the use of 200 mg/kg BW Spirulina in 
combination with ACT led to enhanced antimalarial activity, indicating 
a synergistic interaction between the two treatments.
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